Milestone Scientific, Inc. (MLSS)

NYSE: MLSS · Orthopedic, Prosthetic & Surgical Appliances & Supplies · Livingston, NJ · filing with the SEC since 1996

Full chart Alerts Compare

Grade4.0

◀ Past 2.2● Present 4.4▶ Future 5.1

2 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The grade of Milestone Scientific, Inc.

Nine metrics read from its own filings, by tense

Headline grade

4.0/10

◀ Past2.230% of the headline

● Present4.440% of the headline

▶ Future5.130% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 7 read as filed from the record and 2 are SI estimates, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

2.2/1030% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed

0.7/10

Has it survived what it has been through?

7 warning events since 2017; the latest 2026-05-06.

weight 33% of this tense · 7th percentile among 29 sector filers · read for itself

From the record

Milestone Scientific, Inc.'s filings since 2017 show 7 warning events of 3 kinds: a notice about its exchange listing (8-K item 3.01, 3 times, the latest 2025-10-14); an auditor change (8-K item 4.01, 3 times, the latest 2026-05-06); a late-report notice (Form NT 10-K or NT 10-Q, the latest 2025-03-28) (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed

1.9/10

What has it actually done, year after year?

-2.8% a year over 9 filed years; profitable in 0 of 9.

weight 45% of this tense · 19th percentile among 25 sector filers · read for its customers

From the record

Milestone Scientific, Inc.'s 9 filed years say what it did: revenue went from $11 million in fiscal 2017 to $9 million in fiscal 2025, down 2.8% a year; it rose in 3 of 8 years; the deepest fall was 52% from fiscal 2017 to fiscal 2020; net income was positive in 0 of 9 of those years (its annual reports).

What it rests on

revenue growth over the filed span-2.8%bottom 18% of its family
the share of years revenue rosebottom 6% of its family
the share of filed years with a profitbottom 22% of its family
the deepest fall from a revenue peak51.8%bottom 30% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate

5.2/10

How has it treated the people who own it?

SI estimate 5.2/10, confidence 35 of 100 (one part).

weight 22% of this tense · 52nd percentile among 26 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: Read from one part only, the share count over the years, which ranks in the top 48% of 26 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read: Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned: one part: the share count over the years, the one part on file, ranked among 26 in its family.
Confidence: 35 of 100
What would change it: A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Milestone Scientific, Inc.'s shareholder treatment is put at 5.2 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 48% of 26 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

4.4/1040% of the headline grade · 2 of 3 filed, 1 estimated

Financial health

as filed

4.8/10

Is it financially healthy right now?

ROE -203%: lost 203¢ per shareholder dollar. Leverage 64%: owes 64¢ per asset dollar.

weight 45% of this tense · 48th percentile among 27 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-12-31, Milestone Scientific, Inc. lost about 203 cents for every dollar of shareholders' money, and gross profitability: its products earned about 82 cents per dollar of everything the company owns. Leverage: it owed about 64 cents per dollar of assets, and net share issuance: its share count grew 2.8% over the year (the filed statements).

What it rests on

what it owes per dollar of assetsbottom 23% of its family
return on equitybottom 19% of its family
gross profit against assetstop 6% of its family
the share count against the year beforetop 44% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed

3.2/10

How strong is its position in its industry?

bottom 32% of 26 in its family; net margin -63.8%.

weight 33% of this tense · 32nd percentile among 26 sector filers · read for its customers

From the record

Milestone Scientific, Inc.'s standing among 26 graded names in its industry family: revenue of $9 million in fiscal 2025 ranks in the bottom 29% by size; a net margin of -63.8% ranks in the bottom 33%; revenue growth of 0.6% a year over the last 3 filed years ranks in the bottom 35% (its annual reports).

What it rests on

revenue against the family$9.0Mbottom 29% of its family
net margin-63.8%bottom 33% of its family
three-year revenue growth0.6%bottom 35% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

SI estimate

5.3/10

What are the people in charge doing?

SI estimate 5.3/10, confidence 20 of 100 (family median).

weight 22% of this tense · 50th percentile among 19 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: Fewer than two of the three parts can be read: officer and director changes against the people in charge, the years the people in charge have been filing, the chief executive's years under the title, so the desk assumes the typical reading of its industry family, the median of 19 members with one.
What the record cannot read: Fewer than two of the three parts can be read: officer and director changes against the people in charge, the years the people in charge have been filing, the chief executive's years under the title.
How it was reasoned: family median, 19 readings behind it.
Confidence: 20 of 100
What would change it: Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Milestone Scientific, Inc.'s leadership is put at 5.3 of 10 with a confidence of 20 of 100, because fewer than two of the three parts can be read: officer and director changes against the people in charge, the years the people in charge have been filing, the chief executive's years under the title, so the desk assumes the typical reading of its industry family, the median of 19 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

▶ Future

What are they set up to do next?

5.1/1030% of the headline grade · 3 of 3 filed

Room to expand

as filed

5.0/10

How much room does it have to grow?

top 50% of 25 in its family for room to expand.

weight 45% of this tense · 50th percentile among 25 sector filers · read for itself

From the record

Milestone Scientific, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $1 million against no long-term debt tagged leaves 14.3% of its assets as net cash, top 50% of its family; cash from operations less capital spending is -32.7% of revenue (bottom 38%); a gross margin of 71.4% (top 10%); research spending of 5% of revenue (bottom 24%) (its annual report).

What it rests on

cash less debt against assets14.3%top 50% of its family
cash from operations less capital spending against revenue-32.7%bottom 38% of its family
gross margin71.4%top 10% of its family
research spending against revenue5.0%bottom 24% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

as filed

3.8/10

What could actually drive growth from here?

bottom 38% of 25 in its family for growth drivers.

weight 33% of this tense · 38th percentile among 25 sector filers · read for its customers

From the record

Milestone Scientific, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 0.6% a year over the last three filed years against -2.8% over all 9, speeding up (top 30% of its family); the newest year grew 4% (bottom 46%); research spending grew -26.9% a year (bottom 2%); capital spending grew -0.1% a year (bottom 35%) (its annual reports). Milestone Scientific, Inc. reported 2 lines of business in fiscal 2025: Dental at $9 million (98%), Medical at $183 thousand (2%); 2 of 2 grew against the year before (its annual report).

What it rests on

three-year growth against the whole span+3.5 points a yeartop 30% of its family
the newest year's revenue growth4.0%bottom 46% of its family
three-year growth of research spending-26.9%bottom 2% of its family
three-year growth of capital spending-0.1%bottom 35% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

as filed

7.2/10

Did its newest year beat what its own record pointed to?

top 28% of 23 in its family for expectations against reality.

weight 22% of this tense · 72nd percentile among 23 sector filers · read for its shareholders

From the record

Milestone Scientific, Inc.'s newest year against its own record: revenue of $9 million in fiscal 2025 came in 5% above the $9 million its prior three years' pace pointed to (top 31% of its family); net income of $6 million against a prior three-year average of $7 million (top 33%); a net margin of -63.8% against -74.7% before (top 20%) (its annual reports).

What it rests on

revenue against the prior three years' pace5.0%top 31% of its family
net income against the prior three years' average+16%top 33% of its family
net margin against its prior average+10.9 pointstop 20% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton MLSS · research, not advice